1. Home
  2. ONT vs ABUS Comparison

ONT vs ABUS Comparison

Compare ONT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Onterris Inc. Common Stock

ONT

Onterris Inc. Common Stock

N/A

Current Price

$15.91

Market Cap

758.6M

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$5.22

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONT
ABUS
Founded
N/A
2005
Country
United States
United States
Employees
3500
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
758.6M
839.5M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
ONT
ABUS
Price
$15.91
$5.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
846.6K
2.9M
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
93.69
55.26
EPS
N/A
0.84
Revenue
$830,538,000.00
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$239.71
P/E Ratio
N/A
$6.19
Revenue Growth
19.26
128.21
52 Week Low
$12.68
$3.50
52 Week High
$23.32
$5.45

Technical Indicators

Market Signals
Indicator
ONT
ABUS
Relative Strength Index (RSI) 42.50 66.76
Support Level $12.68 $4.15
Resistance Level $22.67 $5.38
Average True Range (ATR) 1.46 0.18
MACD -0.22 0.07
Stochastic Oscillator 50.93 74.76

Price Performance

Historical Comparison
ONT
ABUS

About ONT Onterris Inc. Common Stock

Onterris Inc is an environmental solutions company. The company provides environmental solutions to organizations addressing regulatory, operational, and environmental challenges. Its services include the application of scientific, engineering, and data-driven approaches to support risk management, compliance, and environmental protection, including air, water, and soil.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: